Trial Details
COMPLETEDBasic Information
| Clinical ID | c4670 |
|---|---|
| Identifier | NCT00160706 |
| Trial Title | A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | BIOLOGICAL: Certolizumab Pegol (CDP870) |
Participant Information
| Sponsor | UCB Pharma SA |
|---|---|
| City | Birmingham |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2004-02 |
|---|---|
| Primary Completion Date | 2012-05 |
| Completion Date | 2012-05 |